European Medicines Agency response to European Ombudsman letter regarding proactive publication of and access to clinical trial data
The European Medicines Agency has published its response to the European Ombudsman’s letter of 13 May 2014 concerning the draft policy on proactive publication of and access to clinical trial data.
In its letter the Agency stresses that the policy is intended to further increase transparency of clinical trial data, and that there is no intention to introduce any hurdle to the implementation of EU legislation on access to documents.
How useful is this page?
Average rating:Based on 0 ratings
Add your rating:
- See all ratings
0 ratings0 ratings0 ratings0 ratings0 ratings